A citation-based method for searching scientific literature

Terry A Jacobson, Sara B Glickstein, Jonathan D Rowe, Paresh N Soni. J Clin Lipidol 2012
Times Cited: 169







List of co-cited articles
1509 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
47


Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Christie M Ballantyne, Harold E Bays, John J Kastelein, Evan Stein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2012
217
35


Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
28


Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
John J P Kastelein, Kevin C Maki, Andrey Susekov, Marat Ezhov, Borge G Nordestgaard, Ben N Machielse, Douglas Kling, Michael H Davidson. J Clin Lipidol 2014
148
24

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Michael Miller, Neil J Stone, Christie Ballantyne, Vera Bittner, Michael H Criqui, Henry N Ginsberg, Anne Carol Goldberg, William James Howard, Marc S Jacobson, Penny M Kris-Etherton,[...]. Circulation 2011
22

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
572
21


Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Luigi Tavazzi, Aldo P Maggioni, Roberto Marchioli, Simona Barlera, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Gian Luigi Nicolosi, Maurizio Porcu, Gianni Tognoni. Lancet 2008
870
19

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
Harold E Bays, Christie M Ballantyne, Rene A Braeckman, William G Stirtan, Paresh N Soni. Am J Cardiovasc Drugs 2013
89
20

Remnant cholesterol as a causal risk factor for ischemic heart disease.
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard. J Am Coll Cardiol 2013
505
17

Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
17

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Bernhard Rauch, Rudolf Schiele, Steffen Schneider, Frank Diller, Norbert Victor, Helmut Gohlke, Martin Gottwik, Gerhard Steinbeck, Ulrike Del Castillo, Rudolf Sack,[...]. Circulation 2010
378
16

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Jacy Crosby, Gina M Peloso, Paul L Auer, David R Crosslin, Nathan O Stitziel, Leslie A Lange, Yingchang Lu, Zheng-zheng Tang, He Zhang, George Hindy,[...]. N Engl J Med 2014
650
15

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
15

Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Anders Sode West, Peer Grande, Børge G Nordestgaard, Anne Tybjærg-Hansen. Eur Heart J 2013
231
15

Triglycerides and cardiovascular disease.
Børge G Nordestgaard, Anette Varbo. Lancet 2014
604
15

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
335
15

Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
358
15

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
277
15

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian,[...]. Clin Cardiol 2018
124
15

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Michael H Davidson, Evan A Stein, Harold E Bays, Kevin C Maki, Ralph T Doyle, Robert A Shalwitz, Christie M Ballantyne, Henry N Ginsberg. Clin Ther 2007
272
14

Safety and efficacy of Omacor in severe hypertriglyceridemia.
W S Harris, H N Ginsberg, N Arunakul, N S Shachter, S L Windsor, M Adams, L Berglund, K Osmundsen. J Cardiovasc Risk 1997
187
14

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Kevin C Maki, David G Orloff, Stephen J Nicholls, Richard L Dunbar, Eli M Roth, Danielle Curcio, Judith Johnson, Douglas Kling, Michael H Davidson. Clin Ther 2013
76
18

Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.
Ethan M Balk, Alice H Lichtenstein, Mei Chung, Bruce Kupelnick, Priscilla Chew, Joseph Lau. Atherosclerosis 2006
442
14

Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
947
14

Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.
David S Siscovick, Thomas A Barringer, Amanda M Fretts, Jason H Y Wu, Alice H Lichtenstein, Rebecca B Costello, Penny M Kris-Etherton, Terry A Jacobson, Mary B Engler, Heather M Alger,[...]. Circulation 2017
293
14

n-3 fatty acids in patients with multiple cardiovascular risk factors.
Maria Carla Roncaglioni, Massimo Tombesi, Fausto Avanzini, Simona Barlera, Vittorio Caimi, Paolo Longoni, Irene Marzona, Valentina Milani, Maria Giuseppina Silletta, Gianni Tognoni,[...]. N Engl J Med 2013
320
13

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard, Anne Tybjærg-Hansen. N Engl J Med 2014
547
13


Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
Yasushi Saito, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Atherosclerosis 2008
204
13

Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.
Evangelos C Rizos, Evangelia E Ntzani, Eftychia Bika, Michael S Kostapanos, Moses S Elisaf. JAMA 2012
649
13

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
13



n-3 fatty acids and cardiovascular events after myocardial infarction.
Daan Kromhout, Erik J Giltay, Johanna M Geleijnse. N Engl J Med 2010
611
12

Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.
Nadeem Sarwar, John Danesh, Gudny Eiriksdottir, Gunnar Sigurdsson, Nick Wareham, Sheila Bingham, S Matthijs Boekholdt, Kay-Tee Khaw, Vilmundur Gudnason. Circulation 2007
898
12

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,[...]. Lancet 2005
12


Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Ann C Skulas-Ray, Peter W F Wilson, William S Harris, Eliot A Brinton, Penny M Kris-Etherton, Chesney K Richter, Terry A Jacobson, Mary B Engler, Michael Miller, Jennifer G Robinson,[...]. Circulation 2019
125
12

Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA.
Benjamin B Albert, José G B Derraik, David Cameron-Smith, Paul L Hofman, Sergey Tumanov, Silas G Villas-Boas, Manohar L Garg, Wayne S Cutfield. Sci Rep 2015
97
11


Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Abbie L Cawood, Ren Ding, Frances L Napper, Ruth H Young, Jennifer A Williams, Matthew J A Ward, Ola Gudmundsen, Runar Vige, Simon P K Payne, Shu Ye,[...]. Atherosclerosis 2010
142
11

Relationships between plasma fatty acid composition and coronary artery disease.
Hiroshige Itakura, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Toru Kita,[...]. J Atheroscler Thromb 2011
155
11

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Rene A Braeckman, Sephy Philip, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano. J Clin Lipidol 2016
32
34

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
M John Chapman, Henry N Ginsberg, Pierre Amarenco, Felicita Andreotti, Jan Borén, Alberico L Catapano, Olivier S Descamps, Edward Fisher, Petri T Kovanen, Jan Albert Kuivenhoven,[...]. Eur Heart J 2011
734
11

Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.
Børge G Nordestgaard, Marianne Benn, Peter Schnohr, Anne Tybjaerg-Hansen. JAMA 2007
11

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Michael Miller, Jean-Claude Tardif, Steven B Ketchum, Ralph T Doyle, Sabina A Murphy, Paresh N Soni,[...]. Clin Cardiol 2017
102
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.